Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
Diana G WangDulce M BarriosVictoria S BlinderJacqueline F BrombergPamela R DrullinskySamuel A FuntKomal L JhaveriDiana E LakeTomas LyonsShanu ModiPedram RazaviMichelle SidelTiffany A TrainaLinda T VahdatMario E LacouturePublished in: Breast cancer research and treatment (2020)
A maculopapular rash associated with increased blood eosinophils occurs frequently with alpelisib. While grade 3 rash leads to alpelisib therapy interruption, dermatologic improvement is evident with systemic corticosteroids; and most patients can continue oncologic treatment at a maintained or reduced dose upon re-challenge with alpelisib.